FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 741 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin April 30, 2026 Grandma Saves Her Money To Put Up A Billboard For Everyone... June 14, 2019 FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML in Paediatric Patients June 23, 2020 Paramedical Tattoo Artist Creates Realistic Nipple Tattoos For Breast Cancer Survivors... May 21, 2019 Load more HOT NEWS Telehealth Can Save People with Cancer Time, Travel, and Money EMA Recommends Granting a Marketing Authorisation for Toripalimab Police Officer Has Bulletproof Vest to Thank for Helping Her Discover... Sisters on Opposite Sides of the Country Diagnosed with Breast Cancer...
